SRZN insider trading
HealthcareSurrozen, Inc./DE: insider trade history from SEC Form 4 filings.
About Surrozen, Inc./DE
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Company website: www.surrozen.com
SRZN insider activity at a glance
FilingIQ tracks 140 insider transactions for SRZN in filings since Aug 13, 2021. The most recent transaction is dated Jul 22, 2026.
Across the full history, 69 open-market purchases
and 13 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SRZN insider trades is 50.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SRZN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading SRZN
Frequently asked
- How many insider trades does FilingIQ track for SRZN?
- FilingIQ tracks 140 Form 4 insider transactions for SRZN (Surrozen, Inc./DE), covering filings from Aug 13, 2021 onwards. 2 of those are dated within the last 90 days.
- Are SRZN insiders net buyers or net sellers?
- Across the full Form 4 history for SRZN, 69 transactions (49%) were open-market purchases and 13 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SRZN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SRZN in?
- Surrozen, Inc./DE (SRZN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $208.20M.
Methodology & sources
Every SRZN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.